{
    "Clinical Trial ID": "NCT00291135",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Letrozole",
        "  Letrozole, 2.5 mg daily for six months"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  evidence of hyperplasia with/without atypia upon random periareolar fine needle aspiration of breast",
        "  on hormone replacement therapy",
        "  postmenopausal",
        "  increased risk of developing breast cancer based on personal or family history",
        "  never have taken aromatase inhibitors or selective estrogen receptor modulators in last six months",
        "  women who have a high risk of breast cancer",
        "  older than 18 years",
        "Exclusion Criteria:",
        "  anticoagulants",
        "  marked breast tenderness",
        "  pregnant or within twelve months of breast feeding/childbirth"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Change in Proliferation of Breast Epithelial Cells Obtained by Random Periareolar Fine Needle Aspiration.",
        "  Proliferation assessment by immunocytochemistry using Ki-67. Expressed as percent of cells staining positive for Ki-67.",
        "  Time frame: Baseline, 6 months",
        "Results 1: ",
        "  Arm/Group Title: Letrozole",
        "  Arm/Group Description: Letrozole, 2.5 mg daily for six months",
        "  Overall Number of Participants Analyzed: 42",
        "  Median (Full Range)",
        "  Unit of Measure: Change in % of cells positive for Ki-67  -2.3        (-21.0 to 7.8)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 0/42 (0.00%)"
    ]
}